Central Nervous System Tumor

Interventional

IRB # STUDY00021117
PNOC 017: A Target Validation/Phase1 Study of BGB-290 in Combination with Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas.

IRB # STUDY00021284
(Advarra-IRB) A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects with Residual or Recurrent Grade 2 Glioma with an IDH1 or IDH2 Mutation.

https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result